Reverse phase protein microarrays designed for targeted therapies in cancer holds promise in the global biochip market in the next 5-10 years. These microarrays provide increased accuracy and enhanced efficacy for the detection of rare molecules as compared to existing microarray surfaces for cancer research & diagnosis to help understand the proteins in tumor cells. Thus, they have helped open the avenues for personalized methods for cancer therapy.
The market of Asia will account for a bulk of the future biochip market growth due to its high growth potential and huge demand from emerging economies such as India and China - the large pool of heterogeneous patient population, and increasing R&D investment in these countries. The top players in the biochip market such as Affymetrix, Inc., Illumina, Inc., and Fluidigm Corporation have relocated their manufacturing base to Singapore to take advantage of the benefits the country offers; coupled with rising demand from neighboring countries of Asia. The players also benefit from a well-established semiconductor manufacturing base including chip technologies. Singapore has made focused efforts to attract life sciences corporates with dedicated investments accounting for 3% of the country's GDP. It came up with its R&D center - Singapore's Biopolis R&D center in 2003-2004 and is home to the Genome Institute of Singapore.
Scope of the report
This research report categorizes the global biochips market on the basis of applications, types, and geography; forecasting revenues and analyzing trends in each of the following submarkets:
On the basis of applications:
DNA applications: Gene expression, SNP genotyping, cancer diagnosis & treatment, genomics, agricultural biotechnology, drug discovery, and oth
Copyright©2010 PR Newswire.
All rights reserved